Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2007) 14 OC8.5

1Military Institute of Health Services, Warsaw, Poland; 2Medical Center of Postgraduate Education, Warsaw, Poland; 3LIM Medical Center, Warsaw, Poland.


Introduction: The patients with inoperable hormone - secreting pituitary tumours are treated with cold somatostatin analogues, but it is not always effective. DOTA-TATE preparation is a somatostatin analogue coupled with β (−) emitter 90 Y. The efficacy of the treatment is based on excessive expression of somatostatin receptors (SSTR) in these tumours.

The aim of the study: To assess the feasibility of treatment of pituitary tumours with 90Y-DOTA-TATE preparation.

Material and methods: 90Y-DOTA-TATE preparation was used in 4 patients with inoperable tumour: 3 patients with acromegaly and 1 with the Nelson’s syndrome. The presence of SSTR was confirmed in scintigraphy with 99 mTc-HYNIC-TATE preparation earlier. Both radiopharmaceuticals are produced by POLATOM – Swierk/Poland. In 2 pts with acromegaly the dose was repeated twice. 1 pt with acromegaly and 1 pt with Nelson’s syndrome were treated with the 90Y-DOTA-TATE four times (3.7 GBq per dose). The renal protection was provided by 10 hours infusion of 1000 ml 10% amino acids preparation with max. speed of 120 ml/h. The local Ethical Committee approval has been obtained before the study.

Results: There were no serious adverse events observed after 90Y-DOTA-TATE treatment. An insignificant, transient decrease of thrombocytes and lymphocytes was noted. In patients with the Nelson’s syndrome the ACTH serum concentration decreased by 31%, in patients with acromegaly GH serum concentration decreased by about 30–40%, and clinical improvement was obtained.

Conclusions: 90Y-DOTA-TATE radiopharmaceutic is feasible and promising in treatment of inoperable pituitary tumours.

Article tools

My recent searches

No recent searches.